24/7 Market News Snapshot 13 March, 2025 – CERo Therapeutics Holdings, Inc. Common Stock (NASDAQ:CERO)

March 13, 2025

DENVER, Colo., 13 March, 2025 (247marketnews.com) – (NASDAQ:CERO) are discussed in this article.
CERo Therapeutics Holdings, Inc. (CERO), a pioneering entity in the field of immunotherapy, is currently experiencing an upward trajectory in the pre-market session, trading at approximately $1.369, marking a gain of about 0.66% from its previous close of $1.360. This promising stock performance is underscored by a robust trading volume of 3.46 million shares, indicating strong investor interest. Technical analysis points to potential support around $1.35 and resistance near $1.40, suggesting that ongoing buying pressure may render CERO an appealing investment opportunity for those seeking growth in the biopharmaceutical sector.

Alongside this favorable market activity, CERo has announced compelling preclinical findings regarding its lead candidate, CER-1236, which were presented at the recent 2025 SITC Spring Scientific Cellular Therapy for Solid Tumors conference. The presentation, entitled “TIM-4-L Expression on Ovarian Cancer Samples can be Targeted by Engineered Chimeric Engulfment Receptor T cells without Toxicity,” showcased the drug’s efficacy in specifically targeting ovarian cancer cells while demonstrating a highly favorable safety profile, confirmed through extensive animal model studies. Notably, assessments post-administration illustrated significant T cell engraftment in lymphoid organs, devoid of any adverse toxic effects as verified by clinical and histopathological evaluations.

CEO Chris Ehrlich expressed enthusiasm regarding these promising results, emphasizing the continued demonstration of CER-1236’s efficacy against cancer cells while underscoring its safety. As the company gears up for its Phase 1 trial in acute myeloid leukemia (AML), the positive findings in treating solid tumors—including ovarian and non-small cell lung cancers—exemplify CERo’s commitment to expanding its clinical landscape. With the initiation of clinical trials on the horizon, CERo Therapeutics remains poised to significantly impact the field of immunotherapy, driving forward innovative treatment solutions for cancer patients.

Related news for (CERO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.